Vilon

Vilon is a synthetic dipeptide (Lys-Glu) from the Khavinson bioregulator family — one of Peptigrity's bioregulator peptides — the shortest peptide in the cluster — researched for immune system modulation, lifespan extension, and gene expression regulation. It is among the better-studied Khavinson bioregulators in terms of long-term rodent lifespan data and human cohort observation. Vilon is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.

What is Vilon and how does the dipeptide bioregulatory mechanism work?

Vilon is a synthetic Lys-Glu dipeptide — the shortest peptide in the Khavinson bioregulator cluster — proposed to enter cell nuclei and modulate gene expression in immune-related pathways. The dipeptide structure provides the most plausible case for nuclear entry given size constraints, and Vilon has been studied as a mechanistic reference compound for the broader bioregulator framework. The Lys-Glu sequence is the N-terminal core shared by longer Khavinson peptides — the tripeptide Vesugen (Lys-Glu-Asp), the tetrapeptide Testagen (Lys-Glu-Asp-Gly), and the tetrapeptide Pancragen (Lys-Glu-Asp-Trp) — each of which extends Lys-Glu with additional residues.

Source: Short Peptides Regulate Gene Expression, Khavinson V.Kh., Linkova N.S., Tarnovskaya S.I. (optional, non-blocking follow-up: confirm full author list), Bulletin of Experimental Biology and Medicine, 2016 · Evidence level: preclinical (rodent lifespan extension, immune markers); Khavinson-group human cohort research; independent replication limited

What does the research show for Vilon?

Preclinical rodent studies from the Khavinson group have reported lifespan extension of 24–42% in some models, reduced tumor incidence, and improved immune function markers in aging rodents. Human cohort data on Vilon comes from Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology, often with Vilon given alongside other bioregulators such as Thymalin and Epithalon, reporting reduced all-cause mortality in elderly populations over 10–15 years. These reports are non-blinded, and some long-follow-up results appear across more than one publication of overlapping cohorts, so the body of independent evidence is smaller than the publication count suggests. No Western-standard randomized controlled trial of Vilon has been published as of August 2026, and independent replication outside this group is limited.

Evidence level: preclinical lifespan extension (rodent); Khavinson-group human cohort studies with long follow-up; independent replication limited

How does Vilon compare to other Khavinson bioregulators?

Vilon is the shortest peptide in the Khavinson cluster (dipeptide) and the most mechanistically referenced for the nuclear-entry hypothesis given its size. It functions as the structural foundation for several longer Khavinson peptides that share the Lys-Glu core.

What are the documented side effects of Vilon?

Side effects in available preclinical and human cohort data are mild — injection-site reactions are the most common report. The favorable safety profile is consistent with the broader Khavinson bioregulator class. Long-term safety has been observed in Khavinson human cohort studies over 10–15 years, with the caveats that apply to non-blinded research.

Evidence level: preclinical safety; Khavinson-group human cohort safety (long follow-up, non-blinded)

What is the regulatory status of Vilon?

Vilon is not approved by the FDA, EMA, or any major Western regulator as of August 2026. Russian clinical research has been conducted. Regulatory context in FDA peptide regulation 2025–2026 timeline.

Why does Vilon vendor verification matter?

Vilon's dipeptide structure (Lys-Glu) is the shortest in the Khavinson cluster, making synthesis straightforward — but the small molecular weight (~275 Da) requires mass spectrometry identity confirmation appropriate to short peptides, where standard peptide-grade analytical methods may have less discrimination than for longer compounds. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Vilon vendors?

Peptigrity collects independent third-party Certificates of Analysis for Vilon from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does Vilon do?

Vilon is proposed to act on immune function and broad cellular aging through epigenetic gene-expression modulation, with preclinical rodent studies reporting lifespan extension of 24–42% and human cohort studies reporting reduced mortality in elderly populations. The human data is from non-blinded Khavinson-group research; FDA-grade Phase 2/3 efficacy has not been established.

Is Vilon the same as Thymalin?

No. Vilon is a synthesized Lys-Glu dipeptide; Thymalin is a polypeptide extract from bovine thymus tissue. Both target immune function but through different molecular forms — Vilon as a defined single-sequence dipeptide, Thymalin as a multi-component extract.

Is Vilon legal to purchase?

Vilon is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Vilon be FDA-approved?

No active FDA approval pathway exists for Vilon as of August 2026.

How can I verify a Vilon vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (expected MW ~275 Da). COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Vilon dose?

No. Vilon is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician. Compare vendors against the independent Vilon lab tests on file.

This section is for educational and informational purposes only and does not constitute medical advice. Vilon is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.